Rhenman & Partners Asset Management AB Sells 350,869 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Rhenman & Partners Asset Management AB lessened its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 29.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 839,131 shares of the biopharmaceutical company's stock after selling 350,869 shares during the period. Rhenman & Partners Asset Management AB owned about 0.64% of Dynavax Technologies worth $10,716,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of DVAX. Norges Bank acquired a new stake in shares of Dynavax Technologies in the fourth quarter valued at about $7,762,000. WINTON GROUP Ltd grew its stake in Dynavax Technologies by 339.0% in the fourth quarter. WINTON GROUP Ltd now owns 426,814 shares of the biopharmaceutical company's stock valued at $5,450,000 after purchasing an additional 329,579 shares in the last quarter. Trexquant Investment LP increased its position in shares of Dynavax Technologies by 48.7% during the 4th quarter. Trexquant Investment LP now owns 776,397 shares of the biopharmaceutical company's stock worth $9,915,000 after purchasing an additional 254,405 shares during the last quarter. Nordea Investment Management AB raised its stake in shares of Dynavax Technologies by 42.7% during the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company's stock worth $10,034,000 after purchasing an additional 232,690 shares in the last quarter. Finally, Barclays PLC grew its stake in shares of Dynavax Technologies by 137.4% in the third quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company's stock valued at $3,371,000 after buying an additional 175,118 shares in the last quarter. 96.96% of the stock is currently owned by institutional investors.

Dynavax Technologies Stock Performance

Shares of DVAX stock traded down $1.05 during midday trading on Thursday, hitting $10.99. 1,860,362 shares of the company were exchanged, compared to its average volume of 2,193,037. Dynavax Technologies Co. has a 52 week low of $9.74 and a 52 week high of $14.63. The firm has a market capitalization of $1.36 billion, a P/E ratio of 60.99 and a beta of 1.26. The firm's 50 day moving average price is $13.28 and its two-hundred day moving average price is $12.57. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting the consensus estimate of $0.05. The company had revenue of $72.03 million for the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. As a group, equities research analysts anticipate that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. William Blair reaffirmed an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. HC Wainwright reaffirmed a "buy" rating and issued a $31.00 target price on shares of Dynavax Technologies in a report on Friday, February 21st. The Goldman Sachs Group cut Dynavax Technologies from a "neutral" rating to a "sell" rating and reduced their price target for the stock from $15.00 to $12.00 in a report on Tuesday, February 11th. Finally, StockNews.com upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Monday, February 24th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.